share_log

ACMA To Offer Board Certification program for Biologics and Biosimilars

PR Newswire ·  Jun 28, 2022 21:30

Board Certified Biologics & Biosimilars Specialist (BCBBS) program will launch in 2022.

NEW YORK, June 28, 2022 /PRNewswire/ -- The Accreditation Council for Medical Affairs (ACMA) announced today that it will launch a new Board Certification program focused on biologics and biosimilars in November 2022. The Board Certified Biologics and Biosimilars Specialist (BCBBS) program will be the first-ever accredited board certification program for healthcare professionals (e.g., pharmacists, prescribers, PhDs, Industry/MSLs etc.) with the goal of creating a new industry standard for effective management of biologics.

Amid the growing use of biologics & biosimilars in clinical practice, the Accreditation Council for Medical Affairs (ACMA) will launch a Board Certification in Biologics & Biosimilars in 2022.

ACMA to launch Board Certified Biologics & Biosimilars Specialist Program for life science & healthcare professionals.

Tweet this

"The ACMA believes that establishing a standard of excellence for the biologics and biosimilars arena will be key as the life sciences industry navigates several obstacles regarding the adoption of biosimilars such as clinical confidence and patient insurance and prior authorization issues," said William Soliman, PhD, BCMAS, ACMA Founder and CEO.

This certification will be the fourth well recognized certification program offered by the ACMA, which has board-certified pharmaceutical professionals in 80+ countries. This board certification is particularly important as analysts predict the global biologics market will continue to grow and register a revenue CAGR of 8.4% during the forecast period, 2021-2028.

Data from Europe and the U.S. over the past 15 years has demonstrated that when providers gain clinical confidence with biosimilars, adoption increases exponentially. A recent market analysis survey of prescribers in the therapeutic areas of oncology, rheumatology, ophthalmology, and diabetes found that while the majority of participating physicians were familiar with biosimilars, prescribing patterns vary by specialty indicating that there is an important need to educate healthcare providers about biosimilars.

About the Accreditation Council for Medical Affairs (ACMA)

The ACMA is a global organization that provides award-winning solutions that provide certification, training, analytics, and insights to support the healthcare and life sciences industries. From Medical Affairs to Market Access, Managed Care, and Market Research, the ACMA has been the standard in the industry for certifying and credentialing prior authorization and medical affairs professionals in over 80+ countries. To learn more about the ACMA visit

Media Contact: Jackie Rogers, MS
Tel: 1-855-255-7137
Email: [email protected]

SOURCE Accreditation Council for Medical Affairs

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment